$GFLT
GenFlat Holdings, Inc.

2022 Q2 Form 10-Q Financial Statement

#000165495422009754 Filed on July 18, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q2
Revenue $1.884K $0.00 $6.408K
YoY Change -70.6%
Cost Of Revenue $1.884K $6.408K
YoY Change -70.6%
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin 0.0% 0.0%
Selling, General & Admin $65.41K $10.48K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $65.41K $10.48K $346.4K
YoY Change -81.12%
Operating Profit -$63.53K -$340.0K
YoY Change -81.31%
Interest Expense $6.740K $970.00 $50.00K
YoY Change -86.52%
% of Operating Profit
Other Income/Expense, Net $10.57K -$8.550K -$445.00
YoY Change -2475.28%
Pretax Income -$52.96K -$926.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$52.96K -$926.0K -$340.4K
YoY Change -84.44% 668.57%
Net Earnings / Revenue -2810.93% -5312.33%
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$0.04
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.33K $26.01K
YoY Change
Cash & Equivalents $25.33K $26.01K $42.91K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $156.7K $165.6K
YoY Change 372.3%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $156.7K $165.6K
Total Long-Term Assets $0.00 $0.00
Total Assets $156.7K $165.6K
YoY Change 372.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $111.8K $76.75K
YoY Change 110.37%
Accrued Expenses $2.891K $35.18K
YoY Change 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $250.0K $225.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $364.7K $336.9K
YoY Change 370.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $364.7K $336.9K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $364.7K $336.9K
YoY Change 370.14%
SHAREHOLDERS EQUITY
Retained Earnings -$3.353M -$3.300M
YoY Change 100.29%
Common Stock $20.85K $20.85K
YoY Change 6.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$208.0K -$171.4K -$55.25K
YoY Change
Total Liabilities & Shareholders Equity $156.7K $165.6K
YoY Change 372.3%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q2
OPERATING ACTIVITIES
Net Income -$52.96K -$926.0K -$340.4K
YoY Change -84.44% 668.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$33.86K -$44.45K -$22.56K
YoY Change 50.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.170K $5.450K
YoY Change
Cash From Investing Activities $8.172K $5.450K -$200.0K
YoY Change -104.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $25.00K 50.00K $230.4K
YoY Change -89.15%
NET CHANGE
Cash From Operating Activities -$33.86K -44.45K -$22.56K
Cash From Investing Activities $8.172K 5.450K -$200.0K
Cash From Financing Activities $25.00K 50.00K $230.4K
Net Change In Cash -$684.00 11.00K $7.859K
YoY Change -108.7%
FREE CASH FLOW
Cash From Operating Activities -$33.86K -$44.45K -$22.56K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
20853 usd
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3107462 usd
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3299684 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-171369 usd
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165566 usd
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
25000 usd
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
175000 usd
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
225000 usd
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
50000 usd
CY2022Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001796949
CY2022Q2 dei Amendment Flag
AmendmentFlag
false
CY2022Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
CY2022Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q2 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20853000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20853000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20853000 shares
CY2021Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
50000 usd
CY2022Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
225000 usd
CY2021Q2 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
50000 usd
CY2022Q2 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
225000 usd
CY2021Q2 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.12 pure
CY2021Q3 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.12 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
CY2022Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2022Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2022Q2 hbr Weighted Average Remaining Term
WeightedAverageRemainingTerm
6.04 years
CY2022Q2 dei Document Type
DocumentType
10-Q
CY2022Q2 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q2 dei Document Period End Date
DocumentPeriodEndDate
2022-05-31
CY2022Q2 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q2 dei Entity File Number
EntityFileNumber
000-56214
CY2022Q2 dei Entity Registrant Name
EntityRegistrantName
Healthcare Business Resources Inc.
CY2022Q2 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3639946
CY2022Q2 dei Entity Address Address Line1
EntityAddressAddressLine1
718 Thompson Lane
CY2022Q2 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 108-273
CY2022Q2 dei Entity Address City Or Town
EntityAddressCityOrTown
Nashville
CY2022Q2 dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
CY2022Q2 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37204
CY2022Q2 dei City Area Code
CityAreaCode
615
CY2022Q2 dei Local Phone Number
LocalPhoneNumber
856-5542
CY2022Q2 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q2 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q2 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q2 dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20853000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20853000 shares
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
1884 usd
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
6408 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18058 usd
CY2021Q2 us-gaap Professional Fees
ProfessionalFees
86588 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
346377 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-63528 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-339969 usd
CY2022Q2 hbr Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
17310 usd
CY2021Q2 hbr Gain Loss On Settlement Of Liabilities
GainLossOnSettlementOfLiabilities
0 usd
CY2022Q2 us-gaap Interest Income Operating
InterestIncomeOperating
0 usd
CY2021Q2 us-gaap Interest Income Operating
InterestIncomeOperating
2532 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
-6740 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
-2977 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10570 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-445 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52958 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-340414 usd
CY2022Q2 hbr Earnings Per Share Basic Diluted
EarningsPerShareBasicDiluted
-0.00
CY2021Q2 hbr Earnings Per Share Basic Diluted
EarningsPerShareBasicDiluted
-0.02
CY2022Q2 hbr Weighted Average Number Of Share Outstanding Basic Diluted
WeightedAverageNumberOfShareOutstandingBasicDiluted
20853000 shares
CY2021Q2 hbr Weighted Average Number Of Share Outstanding Basic Diluted
WeightedAverageNumberOfShareOutstandingBasicDiluted
19699385 shares
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30420 usd
CY2021Q2 hbr Common Shares And Warrants Issued For License Amount
CommonSharesAndWarrantsIssuedForLicenseAmount
38500 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
252852 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-340414 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-55254 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-340414 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
16326 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
252852 usd
CY2022Q2 hbr Increase In Derivative Liabilities
IncreaseInDerivativeLiabilities
17310 usd
CY2021Q2 hbr Increase In Derivative Liabilities
IncreaseInDerivativeLiabilities
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-52958 usd
CY2022Q2 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0 usd
CY2021Q2 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-2532 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
35066 usd
CY2021Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
54653 usd
CY2022Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14980 usd
CY2021Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
12880 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33856 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22561 usd
CY2022Q2 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
0 usd
CY2021Q2 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
200000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-8172 usd
CY2021Q2 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
0 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8172 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-200000 usd
CY2022Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
CY2021Q2 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
200000 usd
CY2022Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
150000 usd
CY2021Q2 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2022Q2 hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
225000 usd
CY2021Q2 hbr Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
0 usd
CY2022Q2 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000 usd
CY2021Q2 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
CY2022Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
CY2021Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
30420 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000 usd
CY2021Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
230420 usd
CY2022Q2 hbr Cash And Cash Equivalents Period Increase Decrease1
CashAndCashEquivalentsPeriodIncreaseDecrease1
-684 usd
CY2021Q2 hbr Cash And Cash Equivalents Period Increase Decrease1
CashAndCashEquivalentsPeriodIncreaseDecrease1
7859 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26013 usd
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35055 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25329 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42914 usd
CY2022Q2 us-gaap Interest Paid
InterestPaid
5135 usd
CY2021Q2 us-gaap Interest Paid
InterestPaid
0 usd
CY2022Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
38500 usd
CY2022Q2 us-gaap Nature Of Operations
NatureOfOperations
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>NOTE 1. NATURE OF BUSINESS AND GOING CONCERN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On September 9, 2019 (commencement of operations), Healthcare Business Resources, Inc. (“we”, “our”, the “Company”), a domestic corporation was organized in Delaware to provide consulting services to healthcare organizations. These services include management consulting related to sales, marketing, business development and advisory board function. The Company’s services are designed to help clients increase revenue, improve overall efficiency and effectiveness of their operations and grow strategically.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On March 5, 2021, HBR Pointclear, LLC, a Delaware limited liability company was incorporated. HBR Pointclear, LLC was formed to enter into an Option Agreement to Purchase Business Assets with PointClear Solutions, Inc.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On June 18, 2021, we and HBR Sub, Inc., a Delaware corporation and our wholly owned subsidiary entered into and closed an Agreement and Plan of Merger (the “Merger Agreement”), with UserTech U.S. LLC, a Delaware limited liability company (“UPlus”) and UPlus Health, LLC, a Delaware limited liability company and a wholly-owned subsidiary of UPlus (“UPlus Health”). Pursuant to the Merger Agreement, and subject to the terms and conditions contained therein, HBR Sub, Inc. was merged with and into UPlus Health, with UPlus Health surviving the merger on the terms and subject to the conditions set forth in the Merger Agreement and certain ancillary agreements. UPlus Health is now our Company’s wholly owned subsidiary. UPlus helps companies across multiple industries with continuous innovation and market development through the implementation of its proprietary technology called the U+Method, which is a is a step-by-step product development methodology that focuses on front–loading the risky parts of product development before starting large buildouts (the “U+Method Technology”). UPlus has licensed to UPlus Health the U+Method Technology and related intellectual property for use in the health care and medical services industry (the “Medical Industry”), pursuant to the license attached to the Merger Agreement as Exhibit A (the “License Agreement”). UPlus and the Company believe that their individual capabilities and expertise could be combined to provide a unique integrated solution to clients in the Medical Industry; and UPlus’ post transaction participation in providing the anticipated integrated solution is set forth in the services agreement (the “Services Agreement”), a copy of which is set forth as Exhibit B to the Merger Agreement. The Company’s post transaction financial metrics plan for UPlus Health and the anticipated integrated solution is set forth in UPlus Health’s financial metrics plan (“Financial Metrics Plan”), a copy of which is set forth as Exhibit C to the Agreement. UPlus Health will be managed by the Company’s current management team. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In this filing, unless context requires otherwise, references to ”we,” “our,” “us” and “our Company” refer to Healthcare Business Resources Inc., a Delaware corporation, and its subsidiaries HBR Pointclear, LLC, HBR Business Development, LLC and UPlus Health, LLC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>Liquidity and Going Concern</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">These consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand is sufficient to fund its planned operations into but not beyond the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern twelve months from the issuance of these consolidated financial statements. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, or other third-party funding.</p>
CY2022Q2 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
25000 usd
CY2021Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
25000 usd
CY2021Q3 us-gaap Debt Instrument Description
DebtInstrumentDescription
Promissory Note will be due and payable two hundred seventy (270) days from the date the principal amount is received by the Company. Interest on the $25,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid.
CY2021Q3 us-gaap Unsecured Debt
UnsecuredDebt
25000 usd
CY2021Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
150000 usd
CY2021Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
150000 usd
CY2021Q3 us-gaap Debt Instrument Description
DebtInstrumentDescription
Promissory Note will be due and payable two hundred seventy (270) days from the date the principal amount is received by the Company. Interest on the $150,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid.
CY2021Q2 us-gaap Debt Instrument Description
DebtInstrumentDescription
principal amount of $50,000 (the “$50,000 Promissory Note”). The principal amount of $50,000 plus all interest under the $50,000 Promissory Note will be due and payable two hundred seventy (270) days from June 10, 2021. Interest on the $50,000 Promissory Note will accrue at a rate of 12.0% per annum, beginning on June 10, 2021, until the principal amount and all accrued but unpaid interest shall have been paid.
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1580000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1580000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.57
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
1097486 shares
CY2022Q2 us-gaap Debt Instrument Description
DebtInstrumentDescription
principal amount of $225,000 (the “$225,000 Promissory Note”). Stephen Epstein, the Company’s Chief Executive Officer, holds a Power of Attorney on behalf of Robert Epstein, who owns and controls RSET Investments QOZB, LLC. The principal amount of $225,000 plus all interest under the $225,000 Promissory Note will be due and payable on December 31, 2023. Interest on the $225,000 Promissory Note will accrue at the greater of rate of 2.0% per annum or the long-term adjusted applicable federal rates for the current month, beginning on the date the principal amount is received by the Company until the principal amount and all accrued but unpaid interest shall have been paid.
CY2022Q2 us-gaap Unsecured Debt
UnsecuredDebt
225000 usd
CY2022Q2 hbr Schedule Of Stock Warrant Activity
ScheduleOfStockWarrantActivity
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Per Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Outstanding at February 28, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,400,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Forfeited and expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Outstanding at May 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,400,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">As of May 31, 2022, the outstanding stock warrants have a weighted average remaining term of 2.08 years and have no intrinsic value.</p>
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2021Q4 hbr Consideration Amount Of Shares
ConsiderationAmountOfShares
10.00
CY2021Q4 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
32000 shares

Files In Submission

Name View Source Status
0001654954-22-009754-index-headers.html Edgar Link pending
0001654954-22-009754-index.html Edgar Link pending
0001654954-22-009754.txt Edgar Link pending
0001654954-22-009754-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hbr-20220531.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hbr-20220531_cal.xml Edgar Link unprocessable
hbr_10q.htm Edgar Link pending
hbr_ex311.htm Edgar Link pending
hbr_ex312.htm Edgar Link pending
hbr_ex321.htm Edgar Link pending
hbr_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hbr-20220531_lab.xml Edgar Link unprocessable
hbr-20220531_pre.xml Edgar Link unprocessable
hbr-20220531_def.xml Edgar Link unprocessable
hbr_10q_htm.xml Edgar Link completed